Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
immunotherapy
lung cancer
malignant pleural effusion
pleural disease
targeted therapy
treatment
Journal
The clinical respiratory journal
ISSN: 1752-699X
Titre abrégé: Clin Respir J
Pays: England
ID NLM: 101315570
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
04
06
2018
revised:
22
01
2019
accepted:
26
01
2019
pubmed:
10
2
2019
medline:
19
6
2019
entrez:
10
2
2019
Statut:
ppublish
Résumé
Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non-small-cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.
Substances chimiques
Antineoplastic Agents
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-138Informations de copyright
© 2019 John Wiley & Sons Ltd.